UNLABELLED: Everolimus downregulates glucose metabolism-associated genes in preclinical models. Inhibition of glucose metabolism measured by (18)F-FDG PET was postulated to serve as a pharmacodynamic marker in everolimus-treated non-small cell lung cancer (NSCLC) patients. METHODS: In 8 NSCLC patients treated with everolimus, the percentage change in (18)F-FDG PET uptake (days 8 and 28 relative to baseline) was determined using a variety of summed standardized uptake value (SUV) measures. Both maximum and mean SUVs were used, with normalizations to body surface area and body weight and with and without correcting for plasma glucose levels. RESULTS: In 5 patients, a reduction of (18)F-FDG PET uptake on day 8 was observed with all methods, ranging from -12.8% to -72.2%. CONCLUSION: These observations demonstrate that inhibition of glucose metabolism is an early effect of everolimus treatment in NSCLC patients and can be assessed using (18)F-FDG PET.
UNLABELLED: Everolimus downregulates glucose metabolism-associated genes in preclinical models. Inhibition of glucose metabolism measured by (18)F-FDG PET was postulated to serve as a pharmacodynamic marker in everolimus-treated non-small cell lung cancer (NSCLC) patients. METHODS: In 8 NSCLCpatients treated with everolimus, the percentage change in (18)F-FDG PET uptake (days 8 and 28 relative to baseline) was determined using a variety of summed standardized uptake value (SUV) measures. Both maximum and mean SUVs were used, with normalizations to body surface area and body weight and with and without correcting for plasma glucose levels. RESULTS: In 5 patients, a reduction of (18)F-FDG PET uptake on day 8 was observed with all methods, ranging from -12.8% to -72.2%. CONCLUSION: These observations demonstrate that inhibition of glucose metabolism is an early effect of everolimus treatment in NSCLCpatients and can be assessed using (18)F-FDG PET.
Authors: Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven Journal: Target Oncol Date: 2010-07-14 Impact factor: 4.493
Authors: Helle-Brit Fiebrich; Ester J M Siemerink; Adrienne H Brouwers; Thera P Links; Wouter S Remkes; Geke A P Hospers; Elisabeth G E de Vries Journal: Oncologist Date: 2011-04-11
Authors: Michael Honer; Thomas Ebenhan; Peter R Allegrini; Simon M Ametamey; Mike Becquet; Catherine Cannet; Heidi A Lane; Terence M O'Reilly; Pius A Schubiger; Melanie Sticker-Jantscheff; Michael Stumm; Paul Mj McSheehy Journal: Transl Oncol Date: 2010-08-01 Impact factor: 4.243
Authors: Taofeek K Owonikoko; Suresh S Ramalingam; Daniel L Miller; Seth D Force; Gabriel L Sica; Jennifer Mendel; Zhengjia Chen; Andre Rogatko; Mourad Tighiouart; R Donald Harvey; Sungjin Kim; Nabil F Saba; Allan Pickens; Madhusmita Behera; Robert W Fu; Michael R Rossi; William F Auffermann; William E Torres; Rabih Bechara; Xingming Deng; Shi-Yong Sun; Haian Fu; Anthony A Gal; Fadlo R Khuri Journal: Clin Cancer Res Date: 2015-02-11 Impact factor: 12.531
Authors: Annelieke E C A B Willemsen; Lioe-Fee de Geus-Oei; Maaike de Boer; Jolien Tol; Yvonne Kamm; Paul C de Jong; Marianne A Jonker; Allert H Vos; Willem Grootjans; Johannes W B de Groot; Sasja F Mulder; Erik H J G Aarntzen; Winald R Gerritsen; Carla M L van Herpen; Nielka P van Erp Journal: Target Oncol Date: 2018-10 Impact factor: 4.493
Authors: Kenya Yamanaka; Marius Petrulionis; Shibo Lin; Chao Gao; Uwe Galli; Susanne Richter; Susanne Winkler; Philipp Houben; Daniel Schultze; Etsuro Hatano; Peter Schemmer Journal: Cancer Med Date: 2013-10-22 Impact factor: 4.452